These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 32887348)

  • 1. Clinical Aspects and Current Therapeutic Approaches for FOP.
    Kitoh H
    Biomedicines; 2020 Sep; 8(9):. PubMed ID: 32887348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
    Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
    J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The congenital great toe malformation of fibrodysplasia ossificans progressiva? - A close call.
    Towler OW; Shore EM; Xu M; Bamford A; Anderson I; Pignolo RJ; Kaplan FS
    Eur J Med Genet; 2017 Jul; 60(7):399-402. PubMed ID: 28473268
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An mTOR Signaling Modulator Suppressed Heterotopic Ossification of Fibrodysplasia Ossificans Progressiva.
    Hino K; Zhao C; Horigome K; Nishio M; Okanishi Y; Nagata S; Komura S; Yamada Y; Toguchida J; Ohta A; Ikeya M
    Stem Cell Reports; 2018 Nov; 11(5):1106-1119. PubMed ID: 30392977
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fibrodysplasia Ossificans Progressiva: A Challenging Diagnosis.
    De Brasi D; Orlando F; Gaeta V; De Liso M; Acquaviva F; Martemucci L; Mastrominico A; Di Rocco M
    Genes (Basel); 2021 Jul; 12(8):. PubMed ID: 34440363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Morpholino-Mediated Exon Skipping Targeting Human ACVR1/ALK2 for Fibrodysplasia Ossificans Progressiva.
    Maruyama R; Yokota T
    Methods Mol Biol; 2018; 1828():497-502. PubMed ID: 30171563
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic advances for blocking heterotopic ossification in fibrodysplasia ossificans progressiva.
    Wentworth KL; Masharani U; Hsiao EC
    Br J Clin Pharmacol; 2019 Jun; 85(6):1180-1187. PubMed ID: 30501012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of osteoclasts in heterotopic ossification enhanced by fibrodysplasia ossificans progressiva-related activin-like kinase 2 mutation in mice.
    Kawao N; Yano M; Tamura Y; Okumoto K; Okada K; Kaji H
    J Bone Miner Metab; 2016 Sep; 34(5):517-25. PubMed ID: 26204847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of Activin A in fibrodysplasia ossificans progressiva: a prominent mediator.
    Lin H; Shi F; Gao J; Hua P
    Biosci Rep; 2019 Aug; 39(8):. PubMed ID: 31341010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. When one skeleton is enough: approaches and strategies for the treatment of fibrodysplasia ossificans progressiva (FOP).
    Kaplan FS; Groppe J; Shore EM
    Drug Discov Today Ther Strateg; 2008; 5(4):255-262. PubMed ID: 23599718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. From mysteries to medicines: drug development for fibrodysplasia ossificans progressive.
    Kaplan FS; Pignolo RJ; Shore EM
    Expert Opin Orphan Drugs; 2013 Aug; 1(8):637-649. PubMed ID: 24800180
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid Progression of Heterotopic Ossification in Severe Variant of Fibrodysplasia Ossificans Progressiva with p.Arg258Gly in ACVR1: A Case Report and Review of Clinical Phenotypes.
    Hasegawa K; Tanaka H; Futagawa N; Miyahara H; Tsukahara H
    Case Rep Genet; 2022; 2022():5021758. PubMed ID: 36060212
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fibrodysplasia ossificans progressiva: middle-age onset of heterotopic ossification from a unique missense mutation (c.974G>C, p.G325A) in ACVR1.
    Whyte MP; Wenkert D; Demertzis JL; DiCarlo EF; Westenberg E; Mumm S
    J Bone Miner Res; 2012 Mar; 27(3):729-37. PubMed ID: 22131272
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterotopic Ossification in Mouse Models of Fibrodysplasia Ossificans Progressiva.
    Chakkalakal SA; Shore EM
    Methods Mol Biol; 2019; 1891():247-255. PubMed ID: 30414138
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Neofunction of ACVR1 in fibrodysplasia ossificans progressiva.
    Hino K; Ikeya M; Horigome K; Matsumoto Y; Ebise H; Nishio M; Sekiguchi K; Shibata M; Nagata S; Matsuda S; Toguchida J
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15438-43. PubMed ID: 26621707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fibrodysplasia Ossificans Progressiva (FOP): A Segmental Progeroid Syndrome.
    Pignolo RJ; Wang H; Kaplan FS
    Front Endocrinol (Lausanne); 2019; 10():908. PubMed ID: 31998237
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiographic characteristics of the hand and cervical spine in fibrodysplasia ossificans progressiva.
    Mishima K; Kitoh H; Haga N; Nakashima Y; Kamizono J; Katagiri T; Susami T; Matsushita M; Ishiguro N
    Intractable Rare Dis Res; 2014 May; 3(2):46-51. PubMed ID: 25343126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recent Topics in Fibrodysplasia Ossificans Progressiva.
    Katagiri T; Tsukamoto S; Nakachi Y; Kuratani M
    Endocrinol Metab (Seoul); 2018 Sep; 33(3):331-338. PubMed ID: 30229572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Expansion of Heterotopic Bone in Fibrodysplasia Ossificans Progressiva Is Activin A-Dependent.
    Upadhyay J; Xie L; Huang L; Das N; Stewart RC; Lyon MC; Palmer K; Rajamani S; Graul C; Lobo M; Wellman TJ; Soares EJ; Silva MD; Hesterman J; Wang L; Wen X; Qian X; Nannuru K; Idone V; Murphy AJ; Economides AN; Hatsell SJ
    J Bone Miner Res; 2017 Dec; 32(12):2489-2499. PubMed ID: 28782882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Development of Macrocycle Kinase Inhibitors for ALK2 Using Fibrodysplasia Ossificans Progressiva-Derived Endothelial Cells.
    Sánchez-Duffhues G; Williams E; Benderitter P; Orlova V; van Wijhe M; Garcia de Vinuesa A; Kerr G; Caradec J; Lodder K; de Boer HC; Goumans MJ; Eekhoff EMW; Morales-Piga A; Bachiller-Corral J; Koolwijk P; Bullock AN; Hoflack J; Ten Dijke P
    JBMR Plus; 2019 Nov; 3(11):e10230. PubMed ID: 31768489
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.